$JBIO Cashflow Statement | Understand Stock

$JBIO

$14.74 +$0.24 (1.66%) Close

$JBIO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statement Of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of Convertible Notes payable
Stock-based compensation expense
Non-cash lease expense
Accretion/amortization on investments
Depreciation expense
Impairment of right-of-use asset
Accretion of discounts and amortization of premiums on investments, net
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses and other current liabilities
Operating lease asset and liability, net
Operating lease assets and liabilities, net
Other liabilities
Operating lease liabilities
Related party accrued expenses and other current liabilities
Net cash used in operating activities

Cash flows from investing activities:
Purchases of short-term investments
Maturities of short-term investments
Purchases of investments
Proceeds from sales/maturities of investments
Payment of security deposit
Purchases of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from sale of Series A redeemable convertible preferred stock, net of issuance costs
Proceeds from sale of common stock in connection with ATM, net
Payments for offering costs
Proceeds from the Pre-Closing Financing, net of $14,548 offering costs
Proceeds from the PIPE Financing, net of offering costs
December 2025 PIPE Financing
October 2025 PIPE Financing
Proceeds from stock option exercises
Proceeds from ESPP issuances
Cash acquired in connection with the reverse recapitalization
Net cash provided by financing activities

Effect of exchange rates on cash and cash equivalents
Net increase in cash and cash equivalents
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the period
Supplemental disclosure of non-cash operating and financing activities:
Unpaid offering costs
Deferred offering costs reclassified from other assets to equity
Operating lease liability arising from obtaining right-of-use asset
Deferred offering costs included in accounts payable
Purchases of property and equipment in accounts payable
Conversion of redeemable convertible preferred stock to common stock upon initial public offering
Assets acquired in connection with the reverse recapitalization
Other liabilities assumed in connection with the reverse recapitalization
Reclassification of warrant liability
Convertible note principal and non-cash accrued interest converted to common stock and pre-funded warrants
Non-cash exchange of Pre-Merger Jade Series Seed Convertible Preferred Stock for Company Series A Non-Voting Convertible Preferred Stock

Comments